Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2

被引:252
作者
Merino, Delphine
Lalaoui, Najoua
Morizot, Alexandre
Schneider, Pascal
Solary, Eric
Micheau, Olivier [1 ]
机构
[1] Univ Bourgogne, INSERM U517, F-21000 Dijon, France
[2] Univ Lausanne, Dept Biochem, CH-1066 Epalinges, Switzerland
关键词
D O I
10.1128/MCB.00520-06
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF family that induces cancer cell death by apoptosis with some selectivity. TRAIL-induced apoptosis is mediated by the transmembrane receptors death receptor 4 (DR4) (also known as TRAIL-R1) and DR5 (TRAIL-R2). TRAIL can also bind decoy receptor 1 (DcR1) (TRAIL-R3) and DcR2 (TRAIL-R4) that fail to induce apoptosis since they lack and have a truncated cytoplasmic death domain, respectively. In addition, DcR1 and DcR2 inhibit DR4- and DR5-mediated, TRAIL-induced apoptosis and we demonstrate here that this occurs through distinct mechanisms. While DcR1 prevents the assembly of the death-inducing signaling complex (DISC) by titrating TRAIL within lipid rafts, DcR2 is corecruited with DR5 within the DISC, where it inhibits initiator caspase activation. In addition, DcR2 prevents DR4 recruitment within the DR5 DISC. The specificity of DcR1- and DcR2-mediated TRAIL inhibition reveals an additional level of complexity for the regulation of TRAIL signaling.
引用
收藏
页码:7046 / 7055
页数:10
相关论文
共 51 条
[1]   Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy [J].
Almasan, A ;
Ashkenazi, A .
CYTOKINE & GROWTH FACTOR REVIEWS, 2003, 14 (3-4) :337-348
[2]   CD8β endows CD8 with efficient coreceptor function by coupling T cell receptor/CD3 to raft-associated CD8/p56lck complexes [J].
Arcaro, A ;
Grégoire, C ;
Bakker, TR ;
Baldi, L ;
Jordan, M ;
Goffin, L ;
Boucheron, N ;
Wurm, F ;
van der Merwe, PA ;
Malissen, B ;
Luescher, IF .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (10) :1485-1495
[3]   Safety and antitumor activity of recombinant soluble Apo2 ligand [J].
Ashkenazi, A ;
Pai, RC ;
Fong, S ;
Leung, S ;
Lawrence, DA ;
Masters, SA ;
Blackie, C ;
Chang, L ;
McMurtrey, AE ;
Hebert, A ;
DeForge, L ;
Koumenis, IL ;
Lewis, D ;
Harris, L ;
Bussiere, J ;
Koeppen, H ;
Shahrokh, Z ;
Schwall, RH .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162
[4]   A unified model for apical caspase activation [J].
Boatright, KM ;
Renatus, M ;
Scott, FL ;
Sperandio, S ;
Shin, H ;
Pedersen, IM ;
Ricci, JE ;
Edris, WA ;
Sutherlin, DP ;
Green, DR ;
Salvesen, GS .
MOLECULAR CELL, 2003, 11 (02) :529-541
[5]   TRAIL receptor-2 signals apoptosis through FADD and caspase-8 [J].
Bodmer, JL ;
Holler, N ;
Reynard, S ;
Vinciguerra, P ;
Schneider, P ;
Juo, P ;
Blenis, J ;
Tschopp, J .
NATURE CELL BIOLOGY, 2000, 2 (04) :241-243
[6]   Progressive resistance of BTK-143 osteosarcoma cells to Apo2L/TRAIL-induced apoptosis is mediated by acquisition of DcR2/TRAIL-R4 expression: resensitisation with chemotherapy [J].
Bouralexis, S ;
Findlay, DM ;
Atkins, GJ ;
Labrinidis, A ;
Hay, S ;
Evdokiou, A .
BRITISH JOURNAL OF CANCER, 2003, 89 (01) :206-214
[7]   Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway [J].
Chaudhary, PM ;
Eby, M ;
Jasmin, A ;
Bookwalter, A ;
Murray, J ;
Hood, L .
IMMUNITY, 1997, 7 (06) :821-830
[8]   Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis [J].
Clancy, L ;
Mruk, K ;
Archer, K ;
Woelfel, M ;
Mongkolsapaya, J ;
Screaton, G ;
Lenardo, MJ ;
Chan, FKM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (50) :18099-18104
[9]   Overexpression of DcR1 and survivin in genetically modified cells with pleiotropic drug resistance [J].
Davidovich, IA ;
Levenson, AS ;
Levenson, VV .
CANCER LETTERS, 2004, 211 (02) :189-197
[10]   The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain [J].
Degli-Esposti, MA ;
Dougall, WC ;
Smolak, PJ ;
Waugh, JY ;
Smith, CA ;
Goodwin, RG .
IMMUNITY, 1997, 7 (06) :813-820